t
On September 20, 2021, GlaxoSmithKline plc's Non-Executive Chairman Sir Jonathan Symonds and eight other Non-Executive Directors acquired a total of 4,999.105 notional Ordinary Shares at £13.94 each and 3,371.115 notional American Depositary Shares (ADSs) at $39.09 each. These acquisitions were made under the company's share allocation arrangements for their period of service from July 1, 2021, to September 30, 2021.
| Date | 22 Sept 2021 |
| Time | 15:58:02 |
| Category | Director/PDMR dealings |
| ID | 6600M |
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Sir Jonathan Symonds |
|||
|
b) |
Position/status |
Non-Executive Chairman
|
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.94 |
3,138.451 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Charles Bancroft |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.09 |
1,479.486 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Vindi Banga |
|||
|
b) |
Position/status |
Senior Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.94 |
650.108 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Anne Beal |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.09 |
200.787 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Vivienne Cox |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.94 |
605.273 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms Lynn Elsenhans |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.09 |
285.330 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Laurie Glimcher |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.09 |
1,056.776 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Jesse Goodman |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.09 |
348.736 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Urs Rohner |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.94 |
605.273 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-09-20 |
|||
|
f) |
Place of the transaction
|
N/A |
|||